🔗 Share this article World Health Organization Raises Warning Over Critical Shortage of Weight-Loss Medications Fewer than 10% of patients who could benefit from obesity jabs such as Wegovy have access to them, caution the World Health Organization as it releases its inaugural recommendations on the medications. Given in excess of 1,000,000,000 individuals worldwide now living with obesity, it is urging more widespread and fairer availability to this class of drugs. Based on forecasts, more than two billion will be obese by 2030 unless action is taken. "Our new guidelines recognises that excess weight is a chronic disease that can be treated with holistic and ongoing support," stated WHO director-general Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and distribution challenges are major barriers to universal access to the treatments that can aid individuals in losing considerable body mass, says the agency. Skinny Jab Shortage Even in the current most optimistic case, the manufacturing of such drugs would only suffice for about 100 million people – under 10% of the global need, as stated by the health organization. The recommendation calls on governments and firms to expand access, by strategies like patent sharing. Exclusive production rights on semaglutide – the primary component of the drug Wegovy – is set to lapse in a number of nations in 2026. The Way Weight-Loss Injections Work The injections replicate a biological compound to reduce digestion speed, curb appetite and increase feelings of fullness so individuals consume fewer calories. Patients usually see weight reduction in the initial weeks of beginning the weekly injections. Evidence suggests patients may put most of the weight back on a year later of discontinuing the medication, because their typical appetite resume. Being overweight or obese elevates your chance for experiencing diseases, including diabetes, cardiovascular issues, stroke, and certain cancers. Excess weight concerns people in countries worldwide and was linked to millions of fatalities worldwide in 2024, according to the WHO.
Fewer than 10% of patients who could benefit from obesity jabs such as Wegovy have access to them, caution the World Health Organization as it releases its inaugural recommendations on the medications. Given in excess of 1,000,000,000 individuals worldwide now living with obesity, it is urging more widespread and fairer availability to this class of drugs. Based on forecasts, more than two billion will be obese by 2030 unless action is taken. "Our new guidelines recognises that excess weight is a chronic disease that can be treated with holistic and ongoing support," stated WHO director-general Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and distribution challenges are major barriers to universal access to the treatments that can aid individuals in losing considerable body mass, says the agency. Skinny Jab Shortage Even in the current most optimistic case, the manufacturing of such drugs would only suffice for about 100 million people – under 10% of the global need, as stated by the health organization. The recommendation calls on governments and firms to expand access, by strategies like patent sharing. Exclusive production rights on semaglutide – the primary component of the drug Wegovy – is set to lapse in a number of nations in 2026. The Way Weight-Loss Injections Work The injections replicate a biological compound to reduce digestion speed, curb appetite and increase feelings of fullness so individuals consume fewer calories. Patients usually see weight reduction in the initial weeks of beginning the weekly injections. Evidence suggests patients may put most of the weight back on a year later of discontinuing the medication, because their typical appetite resume. Being overweight or obese elevates your chance for experiencing diseases, including diabetes, cardiovascular issues, stroke, and certain cancers. Excess weight concerns people in countries worldwide and was linked to millions of fatalities worldwide in 2024, according to the WHO.